GlassScriptPhysician profile
Edward D Manzella
NPI 1962487264
$5,069.65
in general payments reported to CMS, 2019-2025
29 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.15 · 2020: $62.37 · 2021: $338 · 2022: $301 · 2023: $477 · 2024: $1,447 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,397.67 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $726.88 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $447.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bausch Health US, LLC | $338.62 | 2021-2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $270.61 | 2024-2025 | Rexulti |
| Amgen INC. | $179.52 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $174.11 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $167.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.59 | 2023-2025 | Jardiance |
| Verona Pharma, INC. | $162.05 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $146.83 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $128.32 | 2025 | Gemtesa, Myfembree |
| Phathom Pharmaceuticals, INC. | $87.27 | 2024-2025 | Voquezna |
| Abbott Laboratories | $84.65 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biodelivery Sciences International, INC. | $72.08 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.51 | 2025 | Rexulti |
| Astellas Pharma US INC | $52.09 | 2024 | Veozah |
| Radius Health, INC. | $50.14 | 2024 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.09 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $46.89 | 2025 | Camzyos |
| Pfizer INC. | $42.28 | 2025 | |
| Inspire Medical Systems, INC. | $42.10 | 2025 | Inspire |
| Madrigal Pharmaceuticals | $37.82 | 2025 | Rezdiffra |
| Genzyme Corporation | $32.76 | 2024 | |
| Medtronic, INC. | $28.93 | 2025 | Minimed 780g |
| Almatica Pharma LLC | $20.68 | 2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $20.36 | 2024 | Spravato |
| Hikma Pharmaceuticals USA | $18.49 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.76 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Manzella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.